Correlation between the progression of diabetic retinopathy and inflammasome biomarkers in vitreous and serum - a systematic review

BMC Ophthalmol. 2022 May 27;22(1):238. doi: 10.1186/s12886-022-02439-2.

Abstract

Activation of the NOD-like receptor protein 3 (NLRP3) inflammasome pathway has been implicated in Diabetic retinopathy (DR) pathogenesis, but its impact on DR development and progression remains unclear. Therefore, the primary aim of this systematic literature review was to determine the role of the inflammasome in DR development. Furthermore, the secondary aim was to determine whether systemic inflammasome activity can be used to predict DR progression. Studies measuring vitreous and/or serum inflammasome biomarkers in DR patients with Type 2 Diabetes Mellitus (T2DM) were searched systematically using online databases EMBASE, PubMed and Web of Science with the last search conducted on 29th of September 2021. The risk of bias was assessed using the Newcastle Ottawa Scale and 20 studies were eligible for narrative analysis. Limitations included the heterogeneity in detection assays used, the small and uneven sample size, a lack of vitreous data in earlier disease stages, and not accounting for patients with other systemic co-morbidities. Analysis showed that inflammasome biomarkers IL-1β and IL-18 increased significantly from non-proliferative DR to proliferative DR in both vitreous and serum, suggesting the inflammasome pathway is activated as DR progresses and that serum inflammasome levels could be explored as potential biomarkers for DR progression.

Keywords: Biomarkers; Cytokines; Diabetic retinopathy; Inflammasome; Serum; Vitreous.

Publication types

  • Systematic Review

MeSH terms

  • Biomarkers / metabolism
  • Diabetes Mellitus, Type 2* / complications
  • Diabetic Retinopathy* / pathology
  • Humans
  • Inflammasomes

Substances

  • Biomarkers
  • Inflammasomes